Vaxcyte Stock Market Value
| PCVX Stock | USD 54.10 0.85 1.55% |
| Symbol | Vaxcyte |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vaxcyte. Anticipated expansion of Vaxcyte directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Vaxcyte assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Vaxcyte requires distinguishing between market price and book value, where the latter reflects Vaxcyte's accounting equity. The concept of intrinsic value - what Vaxcyte's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Vaxcyte's price substantially above or below its fundamental value.
It's important to distinguish between Vaxcyte's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Vaxcyte should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Vaxcyte's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Vaxcyte 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Vaxcyte's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Vaxcyte.
| 11/19/2025 |
| 02/17/2026 |
If you would invest 0.00 in Vaxcyte on November 19, 2025 and sell it all today you would earn a total of 0.00 from holding Vaxcyte or generate 0.0% return on investment in Vaxcyte over 90 days. Vaxcyte is related to or competes with Crispr Therapeutics, Arrowhead Pharmaceuticals, PTC Therapeutics, Krystal Biotech, TG Therapeutics, Alkermes Plc, and Crinetics Pharmaceuticals. Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacte... More
Vaxcyte Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Vaxcyte's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Vaxcyte upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.39 | |||
| Information Ratio | 0.1063 | |||
| Maximum Drawdown | 15.14 | |||
| Value At Risk | (3.12) | |||
| Potential Upside | 6.71 |
Vaxcyte Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Vaxcyte's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Vaxcyte's standard deviation. In reality, there are many statistical measures that can use Vaxcyte historical prices to predict the future Vaxcyte's volatility.| Risk Adjusted Performance | 0.1115 | |||
| Jensen Alpha | 0.3158 | |||
| Total Risk Alpha | 0.1587 | |||
| Sortino Ratio | 0.1371 | |||
| Treynor Ratio | 0.3232 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Vaxcyte's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Vaxcyte February 17, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1115 | |||
| Market Risk Adjusted Performance | 0.3332 | |||
| Mean Deviation | 2.38 | |||
| Semi Deviation | 2.2 | |||
| Downside Deviation | 2.39 | |||
| Coefficient Of Variation | 775.29 | |||
| Standard Deviation | 3.08 | |||
| Variance | 9.51 | |||
| Information Ratio | 0.1063 | |||
| Jensen Alpha | 0.3158 | |||
| Total Risk Alpha | 0.1587 | |||
| Sortino Ratio | 0.1371 | |||
| Treynor Ratio | 0.3232 | |||
| Maximum Drawdown | 15.14 | |||
| Value At Risk | (3.12) | |||
| Potential Upside | 6.71 | |||
| Downside Variance | 5.71 | |||
| Semi Variance | 4.86 | |||
| Expected Short fall | (3.10) | |||
| Skewness | 0.4081 | |||
| Kurtosis | 0.5555 |
Vaxcyte Backtested Returns
Vaxcyte appears to be very steady, given 3 months investment horizon. Vaxcyte owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.0743, which indicates the firm had a 0.0743 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Vaxcyte, which you can use to evaluate the volatility of the company. Please review Vaxcyte's Coefficient Of Variation of 775.29, semi deviation of 2.2, and Risk Adjusted Performance of 0.1115 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Vaxcyte holds a performance score of 5. The entity has a beta of 1.2, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Vaxcyte will likely underperform. Please check Vaxcyte's treynor ratio, expected short fall, as well as the relationship between the Expected Short fall and day median price , to make a quick decision on whether Vaxcyte's existing price patterns will revert.
Auto-correlation | -0.59 |
Good reverse predictability
Vaxcyte has good reverse predictability. Overlapping area represents the amount of predictability between Vaxcyte time series from 19th of November 2025 to 3rd of January 2026 and 3rd of January 2026 to 17th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Vaxcyte price movement. The serial correlation of -0.59 indicates that roughly 59.0% of current Vaxcyte price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.59 | |
| Spearman Rank Test | -0.28 | |
| Residual Average | 0.0 | |
| Price Variance | 16.12 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Vaxcyte Stock Analysis
When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.